SunTrust Downgrades Medivation (MDVN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street dips as spiking crude prices revive fears of inflation, rate hike
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Pfizer (PFE) Near Deal to Acquire Medivation (MDVN) for $14 Billion
August 22, 2016 12:33 AM EDTPfizer (NYSE: PFE) is near a deal to acquire Medivation (NASDAQ: MDVN) for just shy of $14 billion in cash, or about $80 per share, according to various media reports late Sunday. A deal could be announced as soon as Monday.
The offer comes at a sharp premium to the $52.50 per... More
Pfizer boosts cancer drug roster with $14 billion Medivation deal
August 21, 2016 6:12 PM EDTBy Ransdell Pierson and Ankur Banerjee
(Reuters) - Pfizer Inc (NYSE: PFE), beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc (NASDAQ: MDVN) for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.
Medivation shares jumped nearly 20 percent to close at $80.42, just shy of the offer price of $81.50 per share. Shares of Pfizer, the largest U.S. drugmaker, were down 0.4 percent at $34.84.
The offer is a 55-percent... More
